Hematopoiesis News 8.47 November 28, 2017 | |
| |
TOP STORYScientists report that targeted deletion of the gene encoding the AAA+-ATPase Atad3a hyperactivated mitophagy in mouse hematopoietic cells. [Nat Immunol] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Smoothened Signaling in the Mouse Osteoblastoid Lineage Is Required for Efficient B Lymphopoiesis Researchers developed a mouse model for conditional ablation of smoothened (Smo) in the osteoblastoid lineage. Depletion of Smo from osteoblastoid cells was associated with profound and selective reductions in the number and proportion of bone marrow B lymphoid progenitors. [Blood] Abstract Scientists showed that the CHK1 inhibitor GDC-0575 enhances cytarabine-mediated killing of AML cells both in vitro and in vivo, thus abrogating any potential chemoresistance mechanisms involving DNA repair. [Nat Commun] Full Article Critical Modulation of Hematopoietic Lineage Fate by Hepatic Leukemia Factor Researchers identified robust expression of the leukemia-associated transcription factor hepatic leukemia factor (Hlf) in normal multipotent hematopoietic progenitors, which was rapidly downregulated upon differentiation. Interference with its normal downregulation revealed Hlf as a strong negative regulator of lymphoid development, while remaining compatible with myeloid fates. [Cell Rep] Full Article | Graphical Abstract Generation of an Osteoblast-Based Artificial Niche that Supports In Vitro B Lymphopoiesis Investigators developed a stable osteoblastic cell line, designated osteoblastic niche 4, which functions as an osteoblast-based artificial niche that supports in vitro B lymphopoiesis. [Exp Mol Med] Full Article Thioredoxin Mitigates Radiation-Induced Hematopoietic Stem Cell Injury in Mice Scientists investigated the effectiveness of thioredoxin in rescuing mice from a lethal dose of total body radiation and in enhancing hematopoietic reconstitution following a lethal dose of irradiation. [Stem Cell Res Ther] Full Article CLINICAL RESEARCHInvestigators analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival of multiple myeloma patients receiving single autologous hematopoietic cell transplant (AHCT) within 12 months after diagnosis and relapsing early post-AHCT, and to identify factors predicting for early vs. late relapses. [Leukemia] Abstract Researchers questioned the extent by which pre-hematopoietic cell transplant (HCT) evidence of minimal residual disease detected by these standard assays, corresponded with post-HCT relapse. They conducted a single center, retrospective study of 166 acute myeloid leukemia patients who underwent HCT. [Blood Cancer J] Full Article The authors assessed the platelet transfusion refractoriness rate in patients undergoing allogeneic hematopoietic stem cell transplantation from different sources. [Ann Hematol] Abstract | |
| |
REVIEWSAutologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis: A Reset to Tolerance? The authors review the literature on immunological changes after autologous hematopoietic stem cell transplantation (ASCT) in diffuse cutaneous systemic sclerosis patients to gain more insight whether changes in immunological parameters can help elucidate the mechanism of action of ASCT. [Immunol Lett] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSAbbVie announced that the American Society of Hematology (ASH) has accepted data from the Phase III MURANO study evaluating venetoclax tablets in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, as an oral, late-breaking presentation. [Press release from AbbVie Inc. discussing research presented at 59th ASH Annual Meeting & Exposition, Atlanta] Press Release | |
| |
INDUSTRY NEWSLLS Funds $46 Million in New Research to Find Cures The Leukemia & Lymphoma Society® (LLS) committed an additional $46 million to fund the most innovative science at leading medical institutions around the world, including Memorial Sloan Kettering Cancer Center in New York, Dana-Farber Cancer Institute in Boston, City of Hope in Duarte, California, and the Walter & Eliza Hall Institute of Medical Research in Australia. [The Leukemia & Lymphoma Society®] Press Release Janssen Biotech, Inc. announced that it has submitted a supplemental Biologics License Application to the FDA for DARZALEX®. This application seeks to expand the current indication, using DARZALEX in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. [Janssen Biotech, Inc.] Press Release | |
| |
POLICY NEWSZimbabwe’s Researchers Hope Political Change Will Revitalize Science Academics optimistic that the end of Robert Mugabe’s authoritarian rule could boost research and international collaboration. [Nature News] Editorial United Kingdom Relies on Science to Revive Flagging Economy The United Kingdom has laid out how it will pour money into research to boost its economy — including cash for artificial intelligence and other high-tech industries — as the country prepares to leave the European Union in 2019. [Nature News] Editorial Nobel Laureates Demand Release of Iranian Scholar Facing Death Sentence Some 75 Nobel prize winners have called on the Iranian government to release Ahmadreza Djalali, a researcher in disaster medicine who was sentenced to death last month. The letter is the latest and most powerful protest against the ruling by the scientific community so far. [Nature News] Editorial
| |
EVENTSNEW Standardization of the Hematopoietic Progenitor Assay Training Course NEW Applications of the Hematopoietic Progenitor Assay Training Course NEW 13th Annual Wisconsin Stem Cell Symposium Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Staff Clinician – Hematology (National Heart, Blood and Lung Institute) Postdoctoral Position – Experimental Clinical Genetics (Lund University) Postdoctoral Scientist – Molecular Genetics of Human T Cell Development (Ghent University) PhD Position – 3D Models of the Stem Cell Niche (Karlsruhe Institute of Technology) PhD Studentships – Cancer Research (University of Cambridge) Staff Scientist – Normal and Malignant Hematopoiesis (University of Copenhagen) Faculty Positions – Hematological Malignancies (University of Alabama at Birmingham) Postdoctoral Fellow – Hematology (University of Tennessee Health Science Center) Postdoctoral Fellowship – Development & Epigenetics (Centre National de la Recherche Scientifique) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|